Stem Cell Transplantation is an indication for drug development with over 20 pipeline drugs currently active. According to GlobalData, preregistered drugs for Stem Cell Transplantation have a 50% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Stem Cell Transplantation compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Stem Cell Transplantation overview
Stem cell transplantation, also known as hematopoietic stem cell transplantation (HSCT), is a procedure involving the infusion of healthy blood-forming stem cells to replace damaged or diseased cells in individuals with certain cancers or severe blood disorders. The process aims to restore normal blood cell production in bone marrow and strengthen the immune system. Stem cells can be sourced from bone marrow, peripheral blood, or umbilical cord blood. Preparing for the transplant often involves chemotherapy or radiation to eliminate diseased cells. Risks include infections, graft-versus-host disease (GVHD), and organ damage. Despite potential complications, stem cell transplantation remains a valuable treatment option offering hope for patients with specific malignancies or hematologic disorders.
For a complete picture of PTSR and LoA scores for drugs in Stem Cell Transplantation, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
